Received May 26, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| TDAP | TDAP (BOOSTRIX) | GLAXOSMITHKLINE BIOLOGICALS | UNK | cx4hl | — |
Administration after Temperature excursion; This non-serious case was reported by a nurse via call center representative and described the occurrence of incorrect storage of drug in a 46-year-old patient who received DTPa (Reduced antigen) (Boostrix) (batch number cx4hl, expiry date 09-NOV-2026) for prophylaxis. On 21-MAY-2025, the patient received Boostrix. On 21-MAY-2025, an unknown time after receiving Boostrix, the patient experienced incorrect storage of drug (Verbatim: Administration after Temperature excursion). The outcome of the incorrect storage of drug was not applicable. This report is made by GSK without prejudice and does not imply any admission or liability for the incident or its consequences. Additional Information: GSK Receipt Date: 21-MAY-2025 A nurse called in to request data about the need to revaccinate a patient after a dose of Boostrix was given after a temperature excursion which led to incorrect storage of drug. The Vaccine Administration Facility is the same as Primary Reporter. Consented to follow up.